Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug could shrink rare joint tumors without surgery

NCT ID NCT05417789

Ongoing Disease control Sponsor: SynOx Therapeutics Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This study tests an investigational drug called emactuzumab for people with a rare joint tumor (TGCT) that can't be removed surgically. About 128 participants will receive either the drug or a placebo to see if it shrinks tumors and improves joint function. The goal is to offer a non-surgical treatment option for this condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TENOSYNOVIAL GIANT CELL TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

synovitis tenosynovial giant cell tumor tenosynovial giant cell tumor, diffuse type

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TGCT

Contacts and locations

Locations

  • AP-HP - Hôpital Cochin - Port-Royal, site Cochin

    Paris, Paris, 75014, France

  • Arthur J.E. Child Comprehensive Cancer Centre

    Calgary, Alberta, T2N 4N1, Canada

  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone

    Palermo, Sicily, 90127, Italy

  • Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes

    Lyon, Rhône, 69373, France

  • Cliniques Universitaires Saint-Luc

    Woluwe-Saint-Lambert, Brussels Capital, 1200, Belgium

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, 20133, Italy

  • Fondazione Policlinico Universitario Campus Bio-Medico

    Rome, Lazio, 00128, Italy

  • Fondazione del Piemonte per l'Oncologia (IRCCS)

    Candiolo, Piedmont, 10060, Italy

  • Hospital Universitari i Politecnic La Fe de Valencia

    Valencia, 46026, Spain

  • Hospital Universitario Fundacion Jimenez Diaz

    Zaragoza, Zaragoza, 50009, Spain

  • Hospital Universitario Virgen del Rocio - PPDS

    Seville, 41013, Spain

  • Hospital de La Santa Creu i Sant Pau

    Barcelona, 8041, Spain

  • IRCCS lstituto Ortopedico Rizzoli

    Bologna, 40136, Italy

  • Institut Bergonie - PPDS

    Bordeaux, Gironde, 33000, France

  • Institut Curie - Hôpital de Paris

    Paris, 75248, France

  • Institut de Cancerologie de Ouest - Saint Herblain

    Saint-Herblain, Loire-Atlantique, 44115, France

  • Istituti Fisioterapici Ospitalieri - IRCCS Istituto Nazionale Tumori Regina Elena

    Rome, Lazio, 00144, Italy

  • Leids Universitair Medisch Centrum

    Leiden, 2333 ZA, Netherlands

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • McGill University Health Centre (MUHC)

    Montreal, Quebec, H1T 2M4, Canada

  • MedStar Washington Hospital Center

    Georgetown, Washington, 20010, United States

  • NextGen Oncology

    Beverly Hills, California, 90212, United States

  • Oncopole Claudius Regaud Oncologie Médicale

    Toulouse, 31059, France

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

  • Seoul National University Hospital

    Seoul, 3080, South Korea

  • Skanes Universitetssjukhus Lund

    Lund, Skåne County, 222 42, Sweden

  • St James's University Hospital

    Leeds, LS9 7TF, United Kingdom

  • Taipei Veterans General Hospital

    Taipei, 112, Taiwan

  • The Ohio State University

    Columbus, Ohio, 43201, United States

  • UNICANCER - Centre Oscar Lambret

    Lille, 59000, France

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California, 90089, United States

  • University College Hospital

    London, NW1 2BU, United Kingdom

  • Universitäts Kinderspital Beider Basel (UKBB)

    Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.